ReNeuron Group plc ReNeuron opens US office (7604Y)
December 08 2017 - 1:01AM
UK Regulatory
TIDMRENE
RNS Number : 7604Y
ReNeuron Group plc
08 December 2017
8 December 2017 AIM: RENE
ReNeuron Group plc
("ReNeuron" or the "Company")
ReNeuron opens US office
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the
development of cell-based therapeutics, is pleased to announce that
it has established an office in Boston, MA, USA. This office will
initially house the Company's US-based clinical, medical and
scientific communications staff and reflects the Company's focus on
clinical development activities in the US across its therapeutic
programmes.
During 2018, the Company plans to have three placebo-controlled
Phase IIb clinical trials running with its CTX and hRPC cell
therapy candidates, in stroke disability and retinal diseases. All
of these studies will be conducted in clinical trial centres across
the US.
The establishment of a US office will enable the Company to more
closely manage its relationships with the clinical research
organisations and others involved in the conduct of these clinical
trials as well as facilitating stronger ties with US-based key
opinion leaders in the Company's areas of therapeutic focus.
Olav Hellebø, Chief Executive Officer of ReNeuron, said:
"We are delighted to have established operations in Boston, one
of the US's most vibrant academic and commercial biotechnology
hubs. The US is a major future market for our cell-based therapies
and a presence on the ground represents a key element of ReNeuron's
clinical and commercial development strategy as our therapeutic
candidates move closer to market."
ENQUIRIES:
ReNeuron +44 (0)20 3819 8400
Olav Hellebø , Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan +44 (0) 20 7466 5000
Mark Court, Sophie Wills, Stephanie Watson
Stifel Nicolaus Europe Limited +44 (0) 20 7710 7600
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint
Broker)
Nplus1 Singer Advisory LLP +44 (0) 20 7496 3000
Mark Taylor (Joint Broker)
About ReNeuron
ReNeuron is a leading, clinical-stage cell therapy development
company. Based in the UK, its primary objective is the development
of novel cell-based therapies targeting areas of significant unmet
or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop
cell-based therapies for significant disease conditions where the
cells can be readily administered "off-the-shelf" to any eligible
patient without the need for additional immunosuppressive drug
treatments. The Company has therapeutic candidates in clinical
development for disability as a result of stroke, for critical limb
ischaemia and for the blindness-causing disease, retinitis
pigmentosa.
ReNeuron is also advancing its proprietary exosome technology
platform as a potential new nanomedicine targeting cancer and as a
potential delivery system for drugs that would otherwise be unable
to reach their site of action.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. Further information on ReNeuron and its products can
be found at www.reneuron.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
UPDOKODKKBDBNBK
(END) Dow Jones Newswires
December 08, 2017 02:01 ET (07:01 GMT)
Reneuron (LSE:RENE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Reneuron (LSE:RENE)
Historical Stock Chart
From Apr 2023 to Apr 2024